Randomised Controlled Trials | Community Health

Randomised controlled trials (RCTs) are a cornerstone of evidence-based medicine, providing the highest level of evidence for the efficacy and safety of medical interventions. By randomly allocating participants to different treatment groups, RCTs reduce selection bias and confounding factors, allowing for more accurate conclusions to be drawn. With over 300,000 RCTs registered on the World Health Organization's (WHO) International Clinical Trials Registry Platform, this methodology has become a crucial tool in the development of new treatments and therapies. According to the National Institutes of Health (NIH), RCTs have been instrumental in advancing our understanding of diseases such as cancer, HIV, and tuberculosis. As of 2022, the global RCT market is projected to reach $44.3 billion by 2025, growing at a compound annual growth rate (CAGR) of 5.5%. The widespread adoption of RCTs has led to significant improvements in patient outcomes, with a study published in the Journal of the American Medical Association (JAMA) finding that RCTs have contributed to a 25% reduction in mortality rates for certain diseases.